Optimization of treatment parameters for Foscan®-PDT of basal cell carcinomas

Lasers in Surgery and Medicine

Volumn 40, Issue 5, 2008, Pages 300-311

  Betz, Christian S ^a,b   Rauschning, Winrich ^c   Stranadko, Evgueni P ^d   Riabov, Mikhail V ^d   Albrecht, Volker ^e   Nifantiev, Nikolay E ^e   Hopper, Colin ^a,f  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Biolitec Pharma Ltd   (Ireland)

^d N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^e Biolitec AG   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Basal cell carcinoma; mTHPC; PDT

Indexed keywords

PHOTOSENSITIZING AGENT; TEMOPORFIN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CYTODIAGNOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ESTHETICS; FEMALE; HUMAN; INJECTION SITE SCAR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PAIN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; REMISSION; SUNBURN; SUNLIGHT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MESOPORPHYRINS; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 46349084499     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20632     Document Type: Article

References (34)

1. Green A, Battistutta D, Hart V, Leslie D, Weedon D. Skin cancer in a subtropical Australian population: Incidence and lack of association with occupation. The Nambour Study Group. Am J Epidemiol 1996;144:1034-1040.
2. Chissov VI, Starinsky VV, Petrova GV. Malignant Tumors in Russia, in 2004 (Morbidity and Mortality). Moscow: Moskovskii nauchno-issledovatel'skii onkologicheskii institut im. P.A. Gertsena. 2006.
3. Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol 1999;135:781-786.
4. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005;294:681-690.
5. Epidemiologisches Krebsregister Saarland. Gesundheitsberichterstattung Saarland, Saarbrücken: Internett GmbH. 2006.
6. Lou PJ, Jones L, Hopper C. Clinical outcomes of photodynamic therapy for head-and-neck cancer. Technol Cancer Res Treat 2003;2:311-317.
7. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
8. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-148.
9. Morton CA. The emerging role of 5-ALA-PDT in dermatology: Is PDT superior to standard treatments? J Dermatolog Treat 2002;13(Suppl 1):25-29.
10. Foley P. Clinical efficacy of methyl aminolevulinate (Met-vix(R)) photodynamic therapy. J Dermatolog Treat 2003;14(Suppl 3):15-22.
11. Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, Langmack K, McKenna K, Moseley H, Pearse AD, Stringer M, Taylor DK, Wong G, Rhodes LE. Guidelines for topical photodynamic therapy: Report of a workshop of the British Photodermatology Group. Br J Dermatol 2002;146:552-567.
12. Ahmadi S, McCarron PA, Donnelly RF, Woolfson AD, McKenna K. Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: A pilot study. Exp Dermatol 2004;13:445-451.
13. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994;69:605-608.
14. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta- aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995;29:53-57.
15. Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ, Deutsch TF, Anderson RR. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: Implications for photodynamic treatment. Arch Dermatol Res 1995;287:665-674.
16. Peng Q, Warloe T, Moan J, Heyerdahl H, Stehen HB, Nesland JM, Giercksky KE. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995;62:906-913.
17. Oseroff AR, Blumenson LR, Wilson BD, Mang TS, Bellnier DA, Parsons JC, Frawley N, Cooper M, Zeitouni N, Dougherty TJ. A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg Med 2006;38:417-426.
18. D'Cruz AK, Robinson MH, Biel MA. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study of 128 patients. Head Neck 2004;26:232-240.
19. Kübler AC, Haase T, Staff C, Kahle B, Rheinwald M, Mühling J. Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Lasers Surg Med 1999;25:60-68.
20. Baas P, Saarnak AE, Oppelaar H, Neering H, Stewart FA. Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: A phase I/II study. Br J Dermatol 2001;145:75-78.
21. Essers BA, Dirksen CD, Nieman FH, Smeets NW, Krekels GA, Prins MH, Neumann HA. Cost-effectiveness of mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol 2006;142:187-194.
22. Triesscheijn M, Ruevekamp M, Antonini N, Neering H, Stewart FA, Baas P. Optimizing meso-tetra-hydroxyphenylchlorin mediated photodynamic therapy for basal cell carcinoma. Photochem Photobiol 2006;82:1686-1690.
23. Wagnieres G, Hadjur C, Grosjean P, Braichotte D, Savary JF, Monnier P, van den Bergh H. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin. Photochem Photobiol 1998;68:382-387.
24. Hopper C. Photodynamic therapy: A clinical reality in the treatment of cancer. Lancet Oncol 2000;1:212-219.
25. Ansell JK, de Jode ML, Grahn MF. Characterisation of a murine model for the rapid assessment of the acute photodynamic response in tumour and muscle. Lasers Med Sci 1997;12:336-341.
26. Ronn AM, Nouri M, Lofgren LA, Steinberg BM, Westerborn A, Windahl A, Shikowitz MJ, Abramson AL. Human tissue levels and plasma pharmacokinetics of temoporfin (Foscan, mTHPC). Lasers Med Sci 1996;11:267-272.
27. Cramers P, Ruevekamp M, Oppelaar H, Dalesio O, Baas P, Stewart FA. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 2003;88:283-290.
28. Lofgren LA, Ronn AM, Abramson AL, Shikowitz MJ, Nouri M, Lee CJ, Batti J, Steinberg BM. Photodynamic therapy using m-tetra(hydroxyphenyl) chlorin. An animal model. Arch Otolaryngol Head Neck Surg 1994;120:1355-1362.
29. Veenhuizen R, Oppelaar H, Ruevekamp M, Schellens J, Dalesio O, Stewart F. Does tumour uptake of Foscan determine PDT efficacy? Int J Cancer 1997;73:236-239.
30. Triesscheijn M, Ruevekamp M, Aalders M, Baas P, Stewart FA. Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response. Photochem Photobiol 2005;81:1161-1167.
31. Collaud S, Juzeniene A, Moan J, Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents 2004;4:301-316.
32. Blant SA, Glanzmann TM, Ballini JP, Wagnieres G, van den Bergh H, Monnier P. Uptake and localisation of mTHPC (Foscan) and its 14C-labelled form in normal and tumour tissues of the hamster squamous cell carcinoma model: A comparative study. Br J Cancer 2002;87:1470-1478.
33. Grapengiesser S, Gudmundsson F, Larkö O, Ericson M, Rosén A, Wennberg A-M. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002;27:493-497.
34. Wennberg AM. Pain, pain relief and other practical issues in photodynamic therapy. Australas J Dermatol 2005;46(Suppl. S3-S4):S23-S25.